0001567619-20-012818.txt : 20200702
0001567619-20-012818.hdr.sgml : 20200702
20200702161357
ACCESSION NUMBER: 0001567619-20-012818
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200701
FILED AS OF DATE: 20200702
DATE AS OF CHANGE: 20200702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ALBRECHT DETLEF
CENTRAL INDEX KEY: 0001286642
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39041
FILM NUMBER: 201009472
MAIL ADDRESS:
STREET 1: SATSUMA PHARMACEUTICALS, INC.
STREET 2: 400 OYSTER POINT BOULEVARD, SUITE 221
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Satsuma Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001692830
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813039831
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 OYSTER POINT BOULEVARD
STREET 2: SUITE 221
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 64080
BUSINESS PHONE: 415-505-0809
MAIL ADDRESS:
STREET 1: 400 OYSTER POINT BOULEVARD
STREET 2: SUITE 221
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 64080
4
1
doc1.xml
FORM 4
X0306
4
2020-07-01
0
0001692830
Satsuma Pharmaceuticals, Inc.
STSA
0001286642
ALBRECHT DETLEF
C/O SATSUMA PHARMACEUTICALS, INC.
400 OYSTER POINT BOULEVARD, SUITE 221
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Medical Officer
Common Stock
2020-07-01
4
M
0
300
4.56
A
20512
D
Common Stock
2020-07-01
4
S
0
300
25.6911
D
20212
D
Common Stock
2020-07-01
4
M
0
600
4.56
A
20812
D
Common Stock
2020-07-01
4
S
0
600
26.9912
D
20212
D
Common Stock
2020-07-01
4
M
0
100
4.56
A
20312
D
Common Stock
2020-07-01
4
S
0
100
27.81
D
20212
D
Stock Option (Right to Buy)
4.56
2020-07-01
4
S
0
1000
0
D
2029-05-16
Common Stock
1000
69468
D
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The transaction was executed in multiple trades in prices ranging from $25.35 to $26.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The transaction was executed in multiple trades in prices ranging from $26.60 to $27.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The option vest and become exercisable in successive, equal monthly installments over four years measured from May 15, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
/s/ Thomas P. O'Neil as Attorney in Fact for Detlef Albrecht, M.D.
2020-07-02